Objectives. Granulomatosis with polyangiitis (GPA) mainly affects white Europeans, but rarely GPA may also affect non-Europeans. This study aimed to describe GPA clinical-biological presentation and outcome in black sub-Saharan Africans and Afro-Caribbeans and in North Africans.
Introduction
Granulomatosis with polyangiitis (GPA) is an ANCAassociated vasculitides (AAV) predominantly affecting small-sized vessels, involving mainly the upper and lower respiratory tracts and the kidneys [1] . GPA mainly affects white Europeans (Caucasian and Hispanic), with mean age at diagnosis of 52 years, but rarely it may also affect non-European patients [2] . Pathophysiology of the disease is complex and multifactorial, with environmental and genetic factors playing a role. A genetic component has been recently demonstrated in the pathogenesis of AAV with polymorphisms in HLA-DP and the genes encoding a1-antitrypsin and PR3 [3] , but this does not explain by itself the occurrence of vasculitis. Previous studies and preferential involvement of upper and lower respiratory tract suggest that environmental exposures may play a role in the occurrence of AAV and affect the clinical-biological phenotype. In addition, descriptive studies showed a northsouth declining gradient in disease incidence in the northern hemisphere and an increase in incidence over time [2] .
In the present work, we aimed to describe GPA clinicalbiological presentation and outcome in white Europeans, North Africans, and black sub-Saharan Africans and AfroCaribbeans, and to investigate potential ethnicity-related differences relative to phenotype and prognosis.
Methods

Patients
This study is based on the French Vasculitis Study Group (FVSG) database. This computerized database includes all patients with systemic vasculitides who were enrolled in FVSG trials and/or referred to the Department of Internal Medicine at Avicenne Hospital (Bobigny, France) until September 2003 and Cochin Hospital (Paris, France) thereafter, and to other Departments of members of the FVSG. Regular updates during follow-up, on at least a yearly basis, are also included in the database. Patients who participated in prospective therapeutic trials gave written informed consent for the collection and analysis of their data. Other patients received oral and written communication informing them of their unrestricted right to ask for the deletion of their data. This survey was conducted in compliance with the protocol of Good Clinical Practices and principles of the Declaration of Helsinki, and was approved by the Institutional Review Board of Paris Ile de France 3. We identified patients who were diagnosed prior to or during July 2014 as having GPA according to the ACR criteria for GPA [4] , and/or the European Medicines Agency algorithm [5] and/or Chapel Hill definitions [1] for GPA. Among 915 GPA patients included in the FVSG database, geographic origin and ethnicity were known for 760 patients, who constitute the French population for this study.
Data collected
Data collected from the FVSG database were the following: demographic characteristics, clinical manifestations at diagnosis of GPA, biological parameters and outcome during follow-up. For demographic characteristics age, sex and geographic origin were collected. We classified patients as white patients of European descent, black patients of sub-Saharan origin and French West Indies origin, and North African patients from Maghreb countries (Morocco, Algeria, Tunisia).
For clinical manifestations at diagnosis of GPA we collected the following data: constitutional symptoms (fever 538. 5 C, weight loss >3 kg during the 3 months preceding diagnosis); myalgias and arthralgias; peripheral neuropathy; CNS involvement; renal involvement; cutaneous symptoms; gastrointestinal manifestations; cardiovascular involvement; ocular involvement; and pulmonary involvement. Each of the organ systems was initially assessed with the Birmingham Vasculitis Activity Score (BVAS).
The biological parameters included were serum creatinine level, CRP level at diagnosis, haemogram and ANCA status (considered to be positive when ANCAs were detected by IF and/or ELISA in the serum at diagnosis). For outcome during follow-up we looked at relapse defined as the re-occurrence or new onset of disease attributable to active vasculitis [6] and death. We collected date of relapse and/or death.
Statistical analysis
Clinical-biological presentations and outcomes of white Europeans vs North Africans and vs black sub-Saharans and Afro-Caribbeans were analysed. Data are presented as means (S.D.) or medians (Q1Q3), as appropriate for continuous variables, and number (%) for qualitative variables. Univariate analysis was performed to assess whether characteristics differed between white Europeans and black sub-Saharans and AfroCaribbeans, and white Europeans and North Africans. The chi-square test or Fisher's exact test was used as appropriate to compare qualitative variables and ANOVA or Wilcoxon's test was used as appropriate to compare continuous variables. Because of the two main comparisons (white Europeans vs black sub-Saharans and AfroCaribbeans, and white Europeans vs North Africans), alpha risk was adjusted and a P < 2.5% was considered statistically significant. Descriptive analysis of time to death or relapse was performed according to the KaplanMeier method. Univariate and multivariate Cox models were performed to assess whether ethnicity was associated with time to relapse. A multivariate model was performed for relapse-free survival adjusted for pulmonary involvement, ENT manifestations, renal involvement and PR3-ANCA, features previously described to be associated with relapse. Hypothesis of proportional hazards was verified. Statistical analyses were computed with R version 3.0. 
Results
Characteristics of patients according to ethnicity
Among the 760 patients with available geographic origin and ethnicity, 689 (91%) were white Europeans, 33 (4.3%) were North Africans and 22 (2.9%) were sub-Saharans (n = 8) or Afro-Caribbeans (French West Indies, n = 14). Nine patients (1%) of Middle Eastern origin and seven patients (1%) from Asia were not compared with white Europeans because of the small number of patients. Characteristics according to ethnicity are detailed in Table 1 .
In comparison with white Europeans, sub-Saharans and Afro-Caribbeans were younger at GPA diagnosis [41.7 (14.7) vs 52.1 (16.0) years; P = 0.003], had more frequent CNS involvement (18 vs 4.3%; P = 0.02), including pachymeningitis (13.6 vs 1.6%; P = 0.009), and subglottic stenosis (19 vs 2.2; P = 0.002), and tended to have more frequent chondritis (19 vs 6%; P = 0.04) and retro-orbital tumour (9.1 vs 0.9%; P = 0.027). Hence, overall severe granulomatous manifestations (38 vs 6.8%; P < 0.0001) were more frequent in sub-Saharans and Afro-Caribbeans, compared with white Europeans. In contrast, sub-Saharans and Afro-Caribbeans had less frequent fever (20 vs 51%; P = 0.01), and tended to have less https://academic.oup.com/rheumatology frequent weight loss (25 vs 51%; P = 0.04), kidney involvement (38 vs 59%; P = 0.09), cardiovascular involvement (0 vs 15%; P = 0.06) and peripheral neuropathy (4.5 vs 22%; P = 0.06). Median serum creatinine levels (68 vs 95 mmol/l; P = 0.002) and BVAS [12.3 (7. 2) vs 19.6 (9.1); P = 0.003] were significantly lower in sub-Saharans and Afro-Caribbeans.
Finally, in comparison with white Europeans, North Africans had only less frequent arthralgias (28 vs 59; P = 0.004) and a tendency to less frequent ANCA positivity (79 vs 91; P = 0.07), whereas no difference was observed for other parameters.
Outcome according to ethnicity
Time to relapse was significantly shorter for black subSaharans and Afro-Caribbeans compared with white Europeans. Crude HR for time to relapse was 1.71 (95% CI: 0.96, 3.05) (P = 0.07) (Fig. 1A) , while after adjustment for pulmonary involvement, ENT involvement, renal involvement and PR3-ANCA status, adjusted HR was 1.96 (95% CI: 1.09, 3.51) (P = 0.02). In contrast, no difference was noted between North Africans and white Europeans [crude HR = 1.17 (95% CI: 0.68, 1.99); P = 0.57, and adjusted HR = 1.12 (95% CI: 0.60, 2.09), P = 0.71] (Fig. 1B) .
Finally, overall survival was not statistically different between black sub-Saharans and Afro-Caribbeans and white Europeans [crude HR = 0.64 (95% CI: 0.14, 3.45); P = 0.67] (Fig. 1C) and between North Africans and white Europeans [crude HR = 0.80 (95% CI: 0.23, 2.91); P = 0.76] (Fig. 1D) .
Discussion
In the present work, we analysed the clinical-biological presentation at diagnosis and outcome of GPA according to geographic origin and ethnicity. We observed a low frequency of GPA among non-white Europeans, and found differences in disease presentation and relapse risk in black patients compared with white Europeans. Importantly, GPA in white Europeans in our series was comparable to demography and clinical-biological presentation from other US or European series on GPA.
The reasons why GPA mainly affects white Europeans and very rarely non-European patients, in particular black patients, remain unknown [2] . Our data support the low frequency of GPA in non-European people, even though this study was not designed to assess the frequency of GPA in multiethnic populations. North African and black patients represented only 4 and 3% of all GPA patients, respectively, whereas white Europeans represented 91% of the patients. However, descriptive and epidemiological studies showed a northsouth declining gradient in disease risk in the northern hemisphere and an increased incidence over time [2] . The role of the genetic component is strongly suspected to explain this, since the results of the largest genome-wide association study that was performed in AAV subjects demonstrated particular polymorphisms, but that study was only performed in subjects of European ancestry [3] .
In AAV, studies on the impact of ethnicity on the presentation and outcome are scarce. Regarding outcome, our results suggest a higher risk of relapse in black compared with white patients, consistent with the observed presentation with less frequent renal involvement and more frequent granulomatous manifestations. Higher risk of relapse was previously demonstrated in patients with lower creatinine levels and positive PR3-ANCA [7, 8] , as well as in patients with predominant granulomatous presentation [8] . These findings suggest that, besides the potential impact of the underlying ethnicity, the observed higher rate of relapse in black patients could be related to the peculiar clinical-biological characteristics at presentation. In microscopic polyangiitis, Hogan et al. [9] showed that predictors of renal survival included ethnicity, with African Americans having a worse outcome compared with Caucasians. However, whatever the cause of chronic kidney disease, black patients were shown to have approximately twice the risk of end-stage renal disease observed among white patients [10] , probably through the expression of high-risk G1/G2 alleles of APOL1 common in African Americans and rare in European Americans. Regarding the overall survival, we did not find any difference between groups. However, it is important to note that black Afro-Americans in our study were 10 years younger than white Europeans. Also, Cao et al. [11] found that, among African Americans with AAV, those with PR3-ANCA had 73.3-fold higher odds of having HLA-DRB1*15 alleles than community-based controls. Interestingly, DRB1*1501 protein was found to bind with high-affinity to amino acid sequences of PR3, and PR3 bound to TNF-a-induced surface expression of DRB1*1501 on neutrophils, suggesting an important role of DRB1*1501 alleles in the pathogenesis of PR3-ANCA vasculitis [11] .
Differences between white and black people in incidence, clinical presentation and outcome have already been reported in inflammatory diseases, mainly in sarcoidosis and SLE. Sarcoidosis shares with GPA the presence of histopathological granulomatous lesions that represent a key hallmark of both diseases. Sarcoidosis is found more frequently and is commonly more severe in black people as compared with Caucasians [12] . In addition, black people were also reported to have poorer long-term prognosis, with higher rate of relapse and mortality as compared with Caucasians [13] , findings also observed in our GPA population.
Regarding SLE, based on the US Medicaid population, disease prevalence was shown to be nearly double in African American compared with white women [14] , and higher rates of damage were observed in African American patients. Recently, variation in mortality according to ethnicity was also examined in SLE [15] , with a risk of death that was significantly higher among black compared with white patients. As suggested for sarcoidosis, evidence for genetic susceptibility loci for SLE were demonstrated in African Americans, supporting the key role of the genetic component in explaining these variations.
Overall, these findings in various inflammatory and/or autoimmune diseases showed differences in the presentation and outcome according to ethnicity.
We acknowledge some limitations of this study, including its retrospective design and potential socioeconomic differences that could partly impact some of the discrepancies observed and that were not included in the analysis. However, for these patients living in France, there was no difference in health care, and treatments received by the patients in the three groups were comparable. In addition, some quantitative values such as BVAS, CRP and serum creatinin levels were missing in the database, and we were not able to indicate how many cases were born in France and how many immigrated. Also, because of the rarity of GPA in black people and in North Africans, differences need to be confirmed in other cohorts of patients. The number of cases for some ethnicities was small, so our results may be affected by a lack of power. However, the database from FVSG includes a large population of AAV patients from various geographic origins, and is representative of AAV in France, with more than 100 different centres collecting data from their patients in this database.
In conclusion, the clinical presentation and outcome of GPA seem to be influenced by geographic origin and ethnicity. This particular presentation and worse outcome might be related to the genetic background. Genomewide association studies focusing on the differences between GPA in black and white people could provide additional data to understand these discrepancies.
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